The company has not filed an annual or quarterly report since its Q3 FY2015 10-Q, filed Nov 19, 2015. Its latest SEC filing is a 10-12G/A from Oct 22, 2026.
10-Q for Q3 FY2015, filed Nov 19, 2015
The sections below describe the company as of the FY2014 annual report.
Researches drug treatments, including peptide therapies for autoimmune conditions and therapies combined with existing drugs for drug-resistant solid tumors, for patients with cancer and other diseases.
10-K for FY2014, filed Apr 15, 2015We are a drug discovery and development company researching two core technologies: Targeted Peptide Technology, or TPT, which is currently…View ↗
Our research indicates that our TPT therapies may be useful in treating autoimmune diseases, or diseases that trigger the body’s immune…View ↗
Additionally, we have one drug research program in clinical stage, which is a MDT therapy that helps, in combination with other drugs, to…View ↗
Our Metabolic Disruption Technology, or MDT, program may be used in combination with a variety of existing drugs and compounds to treat…View ↗
Doctors at Scott & White Healthcare in Temple, Texas, and the Cancer Therapy and Research Center at the University of Texas at San Antonio…View ↗
8-K, filed Mar 30, 2016
John Tynan, the Company’s President, CEO and director, shall be resigning effective April 1, 2016. Mr Tynan does not receive cash…View ↗
8-K, filed May 21, 2015
Effective January 1, 2015, on May 21, 2015, we reinstated the Amended Patent License Agreement with S&W after its termination. In…View ↗
8-K, filed May 18, 2015
We were in compliance with these payment terms, except that the payment due January 1, 2015 was not made. As a result, we received notice…View ↗
Loading...
